

リウマチ内科グループ 英語論文の業績 2020年

- 1) Sugihara T, Hasegawa H, Uchida HA, Yoshifuji H, Watanabe Y, Amiya E, Maejima Y, Konishi M, Murakawa Y, Ogawa N, Furuta S, Katsumata Y, Komagata Y, Naniwa T, Okazaki T, Tanaka Y, Takeuchi T, Nakaoka Y, Arimura Y, Harigai M, Isobe M; Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS). Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. *Arthritis Res Ther.* 7;22(1):72, 2020. doi: 10.1186/s13075-020-02171-6.PMID: 32264967 Free PMC article.
- 2) Ohmura SI, Uehara K, Yamabe T, Tamechika S, Maeda S, Naniwa T. Successful use of short-term add-on tocilizumab for refractory adult-onset still's disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide. *Mod Rheumatol Case Rep.* 4(2):202-207, 2020.
- 3) Naniwa T, Iwagaitsu S, Kajiura M. *Mod Rheumatol.* Successful cessation of tumor necrosis factor inhibitor treatment in rheumatoid arthritis patients and potential predictors for early flare: An observational study in routine clinical care. 30(6):948-958, 2020.